Managing glomerular disease in pregnancy

Nephrology Dialysis Transplantation

Volumn 32, Issue , 2017, Pages I48-I56

  Hladunewich, Michelle A ^a   Bramham, Kate ^b   Jim, Belinda ^c   Maynard, Sharon ^d  

^a UNIVERSITY OF TORONTO   (Canada)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d LEHIGH VALLEY HOSPITAL   (United States)

Author keywords

Biopsy; Glomerular disease; Immunosuppression; Pre eclampsia; Pregnancy

Indexed keywords

COMPLICATION; DISEASE MANAGEMENT; FEMALE; GLOMERULUS; HUMAN; KIDNEY DISEASE; PATHOLOGY; PREGNANCY; PREGNANCY COMPLICATIONS;

DISEASE MANAGEMENT; FEMALE; HUMANS; KIDNEY DISEASES; KIDNEY GLOMERULUS; PREGNANCY; PREGNANCY COMPLICATIONS;

EID: 85030612871     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfw319     Document Type: Review

References (84)

1. Jungers P, Houillier P, Forget D et al. Influence of pregnancy on the course of primary chronic glomerulonephritis. Lancet 1995; 346: 1122-1124
2. Abe S. Pregnancy in IgA nephropathy. Kidney Int 1991; 40: 1098-1102
3. Abe S. The influence of pregnancy on the long-term renal prognosis of IgA nephropathy. Clin Nephrol 1994; 41: 61-64
4. Liu Y, Ma X, Lv J et al. Risk factors for pregnancy outcomes in patients with IgA nephropathy: a matched cohort study. Am J Kidney Dis 2014; 64: 730-736
5. Limardo M, Imbasciati E, Ravani P et al. Pregnancy and progression of IgA nephropathy: results of an Italian multicenter study. Am J Kidney Dis 2010; 56: 506-512
6. Surian M, Imbasciati E, Cosci P et al.. Glomerular disease and pregnancy. A study of 123 pregnancies in patients with primary and secondary glomerular diseases. Nephron 1984; 36: 101-105
7. Abe S, Amagasaki Y, Konishi K et al. The influence of antecedent renal disease on pregnancy. Am J Obstet Gynecol 1985; 153: 508-514
8. Piccoli GB, Cabiddu G, Attini R et al. Risk of adverse pregnancy outcomes in women with CKD. J Am Soc Nephrol 2015; 26: 2011-2022
9. Jones DC, Hayslett JP. Outcome of pregnancy in women with moderate or severe renal insufficiency. N Engl J Med 1996; 335: 226-232
10. Imbasciati E, Gregorini G, Cabiddu G et al. Pregnancy in CKD stages 3 to 5: fetal and maternal outcomes. Am J Kidney Dis 2007; 49: 753-762
11. Koetje PM, Spaan JJ, Kooman JP et al. Pregnancy reduces the accuracy of the estimated glomerular filtration rate based on Cockroft-Gault and MDRD formulas. Reprod Sci 2011; 18: 456-462
12. Cote AM, Lam EM, von Dadelszen P et al. Monitoring renal function in hypertensive pregnancy. Hypertens Pregnancy 2010; 29: 318-329
13. Smith MC, Moran P, Ward MK et al. Assessment of glomerular filtration rate during pregnancy using the MDRD formula. BJOG 2008; 115: 109-112
14. Piccoli GB, Attini R, Vasario E et al. Pregnancy and chronic kidney disease: a challenge in all CKD stages. Clin J Am Soc Nephrol 2010; 5: 844-855
15. Alper AB, Yi Y, Webber LS et al. Estimation of glomerular filtration rate in preeclamptic patients. Am J Perinatol 2007; 24: 569-574
16. Stevens LA, Schmid CH, Greene T et al. Comparative performance of the CKD Epidemiology Collaboration (CKD-EPI) and the Modification of Diet in Renal Disease (MDRD) Study equations for estimating GFR levels above 60 mL/min/1.73 m2. Am J Kidney Dis 2010; 56: 486-495
17. Smith MC, Moran P, Davison JM. EPI-CKD is a poor predictor of GFR in pregnancy. Arch Dis Child Fetal Neonatal Ed 2011; 96 (Suppl 1)
18. Petri M, Howard D, Repke J. Frequency of lupus flare in pregnancy. The Hopkins Lupus Pregnancy Center experience. Arthritis Rheum 1991; 34: 1538-1545
19. Smyth A, Oliveira GH, Lahr BD et al. A systematic review and meta-analysis of pregnancy outcomes in patients with systemic lupus erythematosus and lupus nephritis. Clin J Am Soc Nephrol 2010; 5: 2060-2068
20. Clowse ME, Richeson RL, Pieper C et al. Pregnancy outcomes among patients with vasculitis. Arthritis Care Res (Hoboken) 2013; 65: 1370-1374
21. Fredi M, Lazzaroni MG, Tani C et al. Systemic vasculitis and pregnancy: a multicenter study on maternal and neonatal outcome of 65 prospectively followed pregnancies. Autoimmun Rev 2015; 14: 686-691
22. Imbasciati E, Tincani A, Gregorini G et al. Pregnancy in women with preexisting lupus nephritis: predictors of fetal and maternal outcome. Nephrol Dial Transplant 2009; 24: 519-525
23. Bobrie G, Liote F, Houillier P et al. Pregnancy in lupus nephritis and related disorders. Am J Kidney Dis 1987; 9: 339-343
24. Croft AP, Smith SW, Carr S et al. Successful outcome of pregnancy in patients with anti-neutrophil cytoplasm antibody-associated small vessel vasculitis. Kidney Int 2015; 87: 807-811
25. Oh HJ, Han SH, Yoo DE et al. Reduced pre-pregnancy proteinuria is associated with improving postnatal maternal renal outcomes in IgA nephropathy women. Clin Nephrol 2011; 76: 447-454
26. Zhang JJ, Ma XX, Hao L et al. A systematic review and meta-analysis of outcomes of pregnancy in CKD and CKD outcomes in pregnancy. Clin J Am Soc Nephrol 2015; 10: 1964-1978
27. Packham D, Fairley KF. Renal biopsy: indications and complications in pregnancy. Br J Obstet Gynaecol 1987; 94: 935-939
28. Piccoli GB, Daidola G, Attini R et al. Kidney biopsy in pregnancy: evidence for counselling? A systematic narrative review. BJOG 2013; 120: 412-427
29. Lindheimer MD, Davison JM. Renal biopsy during pregnancy: 'to b … or not to b …?' Br J Obstet Gynaecol 1987; 94: 932-934
30. Al-Rabadi L, Ayalon R, Bonegio RG et al. Pregnancy in a patient with primary membranous nephropathy and circulating anti-PLA2R antibodies: a case report. Am J Kidney Dis 2016; 67: 775-778
31. Kemper MJ, Wei C, Reiser J. Transmission of glomerular permeability factor soluble urokinase plasminogen activator receptor (suPAR) from a mother to child. Am J Kidney Dis 2013; 61: 352
32. Li DK, Yang C, Andrade S et al. Maternal exposure to angiotensin converting enzyme inhibitors in the first trimester and risk of malformations in offspring: a retrospective cohort study. BMJ 2011; 343: d5931
33. Porta M, Hainer JW, Jansson SO et al. Exposure to candesartan during the first trimester of pregnancy in type 1 diabetes: experience from the placebo-controlled diabetic retinopathy candesartan trials. Diabetologia 2011; 54: 1298-1303
34. Hod M, van Dijk DJ, Karp M et al. Diabetic nephropathy and pregnancy: the effect of ACE inhibitors prior to pregnancy on fetomaternal outcome. Nephrol Dial Transplant 1995; 10: 2328-2333
35. Bar J, Chen R, Schoenfeld A et al. Pregnancy outcome in patients with insulin dependent diabetes mellitus and diabetic nephropathy treated with ACE inhibitors before pregnancy. J Pediatr Endocrinol Metab 1999; 12: 659-665
36. Clowse ME, Magder L, Witter F et al. Hydroxychloroquine in lupus pregnancy. Arthritis Rheum 2006; 54: 3640-3647
37. Koh JH, Ko HS, Kwok SK et al. Hydroxychloroquine and pregnancy on lupus flares in Korean patients with systemic lupus erythematosus. Lupus 2015; 24: 210-217
38. Benediktsson R, Calder AA, Edwards CR et al. Placental 11 beta-hydroxysteroid dehydrogenase: a key regulator of fetal glucocorticoid exposure. Clin Endocrinol (Oxf) 1997; 46: 161-166
39. Park-Wyllie L, Mazzotta P, Pastuszak A et al. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology 2000; 62: 385-392
40. Kallen B. Maternal drug use and infant cleft lip/palate with special reference to corticoids. Cleft Palate Craniofac J 2003; 40: 624-628
41. Mariotti V, Marconi AM, Pardi G. Undesired effects of steroids during pregnancy. J Matern Fetal Neonatal Med 2004; 16 (Suppl 2): 5-7
42. Bermas BL. Non-steroidal anti inflammatory drugs, glucocorticoids and disease modifying anti-rheumatic drugs for the management of rheumatoid arthritis before and during pregnancy. Curr Opin Rheumatol 2014; 26: 334-340
43. Vogl SE, Worda C, Egarter C et al. Mode of delivery is associated with maternal and fetal endocrine stress response. BJOG 2006; 113: 441-445
44. Norgard B, Pedersen L, Fonager K et al. Azathioprine, mercaptopurine and birth outcome: a population-based cohort study. Aliment Pharmacol Ther 2003; 17: 827-834
45. Hutson JR, Matlow JN, Moretti ME et al. The fetal safety of thiopurines for the treatment of inflammatory bowel disease in pregnancy. J Obstet Gynaecol 2013; 33: 1-8
46. Hutson JR, Lubetsky A, Walfisch A et al. The transfer of 6-mercaptopurine in the dually perfused human placenta. Reprod Toxicol 2011; 32: 349-353
47. Ostensen M, Khamashta M, Lockshin M et al. Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis Res Ther 2006; 8: 209
48. Webster P, Wardle A, Bramham K et al. Tacrolimus is an effective treatment for lupus nephritis in pregnancy. Lupus 2014; 23: 1192-1196
49. Rao S, Ghanta M, Moritz MJ et al. Long-term functional recovery, quality of life, and pregnancy after solid organ transplantation. Med Clin North Am 2016; 100: 613-629
50. Kim H, Jeong JC, Yang J et al. The optimal therapy of calcineurin inhibitors for pregnancy in kidney transplantation. Clin Transplant 2015; 29: 142-148
51. Hyrich KL, Verstappen SM. Biologic therapies and pregnancy: the story so far. Rheumatology (Oxford) 2014; 53: 1377-1385
52. Hoeltzenbein M, Elefant E, Vial T et al. Teratogenicity of mycophenolate confirmed in a prospective study of the European Network of Teratology Information Services. Am J Med Genet A 2012; 158A: 588-596
53. Anderka MT, Lin AE, Abuelo DN et al. Reviewing the evidence for mycophenolate mofetil as a new teratogen: case report and review of the literature. Am J Med Genet A 2009; 149A: 1241-1248
54. Enns GM, Roeder E, Chan RT et al. Apparent cyclophosphamide (cytoxan) embryopathy: a distinct phenotype? Am J Med Genet 1999; 86: 237-241
55. Clowse ME, Magder L, Petri M. Cyclophosphamide for lupus during pregnancy. Lupus 2005; 14: 593-597
56. Victora CG, Bahl R, Barros AJ et al. Breastfeeding in the 21st century: epidemiology, mechanisms, and lifelong effect. Lancet 2016; 387: 475-490
57. Bramham K, Chusney G, Lee J et al. Breastfeeding and tacrolimus: serial monitoring in breast-fed and bottle-fed infants. Clin J Am Soc Nephrol 2013; 8: 563-567
58. Sau A, Clarke S, Bass J et al. Azathioprine and breastfeeding: is it safe? BJOG 2007; 114: 498-501
59. Noviani M, Wasserman S, Clowse ME. Breastfeeding in mothers with systemic lupus erythematosus. Lupus 2016; 25(9): 973-979
60. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy. Obstet Gynecol 2013; 122: 1122-1131
61. Magee LA, von Dadelszen P, Rey E et al. Less-tight versus tight control of hypertension in pregnancy. N Engl J Med 2015; 372: 407-417
62. Xie RH, Guo Y, Krewski D et al. Association between labetalol use for hypertension in pregnancy and adverse infant outcomes. Eur J Obstet Gynecol Reprod Biol 2014; 175: 124-128
63. Magee LA, von Dadelszen P, Singer J et al. Do labetalol and methyldopa have different effects on pregnancy outcome? Analysis of data from the Control of Hypertension in Pregnancy Study (CHIPS) trial. BJOG 2016; 123: 1143-1151
64. Podymow T, August P, Umans JG. Antihypertensive therapy in pregnancy. Semin Nephrol 2004; 24: 616-625
65. Bortolus R, Ricci E, Chatenoud L et al. Nifedipine administered in pregnancy: effect on the development of children at 18 months. BJOG 2000; 107: 792-794
66. Magee LA, Duley L. Oral beta-blockers for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev 2003; 3:CD002863
67. Bullo M, Tschumi S, Bucher BS et al. Pregnancy outcome following exposure to angiotensin-converting enzyme inhibitors or angiotensin receptor antagonists: a systematic review. Hypertension 2012; 60: 444-450
68. Serreau R, Luton D, Macher MA et al. Developmental toxicity of the angiotensin II type 1 receptor antagonists during human pregnancy: a report of 10 cases. BJOG 2005; 112: 710-712
69. Abbassi-Ghanavati M, Greer LG, Cunningham FG. Pregnancy and laboratory studies: a reference table for clinicians. Obstet Gynecol 2009; 114: 1326-1331
70. Sebestyen A, Varbiro S, Sara L et al. Successful management of pregnancy with nephrotic syndrome due to preexisting membranous glomerulonephritis: a case report. Fetal Diagn Ther 2008; 24: 186-189
71. Ope-Adenuga S, Moretti M, Lakhi N. Management of membranous glomerulonephritis in pregnancy: a multidisciplinary challenge. Case Rep Obstet Gynecol 2015; 2015: 839376
72. Barbour SJ, Greenwald A, Djurdjev O et al. Disease-specific risk of venous thromboembolic events is increased in idiopathic glomerulonephritis. Kidney Int 2012; 81: 190-195
73. National Collaborating Centre for Women's and Children's Health. Hypertension in pregnancy: The management of hypertensive disorders during pregnancy. London: Royal College of Obstetricians and Gynaecologists, 2010.
74. Basude S, Hein C, Curtis SL et al. Low-molecular-weight heparin or war-farin for anticoagulation in pregnant women with mechanical heart valves: what are the risks? A retrospective observational study. BJOG 2012; 119: 1008-1013; discussion 1012-1003
75. Kamel H, Navi BB, Sriram N et al. Risk of a thrombotic event after the 6-week postpartum period. N Engl J Med 2014; 370: 1307-1315
76. Piechota W, Staszewski A. Reference ranges of lipids and apolipoproteins in pregnancy. Eur J Obstet Gynecol Reprod Biol 1992; 45: 27-35
77. Bateman BT, Hernandez-Diaz S, Fischer MA et al. Statins and congenital malformations: cohort study. BMJ 2015; 350: h1035
78. Hershkovitz R, de Swiet M, Kingdom J. Mid-trimester placentation assessment in high-risk pregnancies using maternal serum screening and uterine artery Doppler. Hypertens Pregnancy 2005; 24: 273-280
79. Herraiz I, Lopez-Jimenez EA, Garcia-Burguillo A et al. Role of uterine artery Doppler in interpreting low PAPP-A values in first-trimester screening for Down syndrome in pregnancies at high risk of impaired placentation. Ultrasound Obstet Gynecol 2009; 33: 518-523
80. Piccoli GB, Gaglioti P, Attini R et al. Pre-eclampsia or chronic kidney disease? The flow hypothesis. Nephrol Dial Transplant 2013; 28: 1199-1206
81. Rolfo A, Attini R, Tavassoli E et al. Is it possible to differentiate chronic kidney disease and preeclampsia by means of new and old biomarkers? A prospective study. Dis Markers 2015; 2015: 127083
82. Perni U, Sison C, Sharma V et al. Angiogenic factors in superimposed preeclampsia: a longitudinal study of women with chronic hypertension during pregnancy. Hypertension 2012; 59: 740-746
83. Rolfo A, Attini R, Nuzzo AM et al. Chronic kidney disease may be differentially diagnosed from preeclampsia by serum biomarkers. Kidney Int 2013; 83: 177-181
84. Bramham K, Seed PT, Lightstone L et al. Diagnostic and predictive biomarkers for pre-eclampsia in patients with established hypertension and chronic kidney disease. Kidney Int 2016; 89: 874-885